Posted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence.
BMS is reportedly having a hard time persuading its partner Ono Pharma Korea to resume reimbursement negotiations on Opdivo, an immuno-oncology drug.
On the other hand, Merck Sharp and Dohme has begun renegotiations with the Ministry of Health and Welfare on Opdivo’s competitor, Keytruda.
